History

Boldenone was reportedly patented by Ciba around 1949, with esters developed in the following decades. A human formulation, Parenabol (boldenone undecylenate), was marketed for clinical use in the 1960s but was discontinued for human use by the late 1970s, and there is no modern accepted human medical indication. The compound persists as the FDA-approved veterinary product Equipoise (originally Squibb), an intramuscular preparation for debilitated horses, maintained through FDA's New Animal Drug process.

Boldenone, sold for veterinary use as Equipoise and known informally as “EQ,” is a synthetic anabolic-androgenic steroid (AAS) — a derivative of testosterone, not a peptide and not a SARM. It is used as the long-acting injectable undecylenate ester. It once had a human formulation (Parenabol) but lost human approval decades ago; today its only sanctioned use is in horses. Human physique and performance claims rest on general androgen pharmacology and anecdote rather than any boldenone-specific human trials.

What it is

Boldenone is chemically 1-dehydrotestosterone — testosterone with an added double bond in the A-ring (androsta-1,4-dien-17β-ol-3-one); the federal statute lists it as “boldenone (17β-hydroxyandrost-1,4-diene-3-one).” It is not 17α-alkylated, so it is used as an injectable ester (undecylenate) rather than an oral tablet, and it does not carry the hepatotoxicity profile characteristic of oral 17α-alkylated steroids such as methandienone or stanozolol. Mechanistically it is a classic androgen-receptor (AR) agonist. It is comparatively resistant to 5α-reductase (relatively little conversion to a more potent DHT-type androgen in target tissues) but does aromatize to estrogen, giving it some estrogenic activity. The widely repeated claim that it aromatizes “at about half the rate of testosterone” originates from non-peer-reviewed bodybuilding literature and is not grounded in solid human pharmacokinetic data — treat it as an informal estimate, not an established constant; what is reasonably supported is that it tends to produce less estrogen-driven water retention than testosterone. The undecylenate ester is highly lipophilic and depot-acting, with sources citing a long intramuscular half-life on the order of about 14 days.

The claims

The only sanctioned claim is veterinary: the FDA-approved label is for debilitated horses, as an aid to improve weight, haircoat, and general physical condition. In non-medical human use (off-label and illicit), boldenone is promoted for lean-mass and strength gains and for its appetite-stimulating and erythropoietic (red-cell-raising) effects, valued for a relatively slow, “lean” gain with comparatively lower estrogenic water retention than testosterone. None of these human uses is supported by human efficacy trials.

What the evidence actually shows

The approved indication rests on an animal/veterinary anabolic effect: in debilitated horses, the approved product is labeled to improve weight, haircoat, and general physical condition.

Human efficacy data are essentially absent by modern standards. There are no well-conducted contemporary randomized controlled trials in humans demonstrating boldenone’s effects on lean mass, strength, or any clinical condition. Claims about lean-mass or strength benefits in people are extrapolated from general AAS pharmacology and anecdote, not from boldenone-specific human trials.

Most peer-reviewed, human-relevant boldenone literature is in anti-doping detection and analytical work, not efficacy. There is a substantial body of work on detecting boldenone misuse via its metabolites and on distinguishing exogenous from possible trace endogenous or microbial-origin boldenone (a genuine analytical challenge in doping control), using gas chromatography–mass spectrometry (GC–MS) and isotope-ratio mass spectrometry (IRMS). The broader AAS-class evidence does support real anabolic effects of androgens on muscle, but it also documents the harms below; it is class-level evidence, not boldenone-specific human efficacy data.

Legal and regulatory status

In the United States, anabolic steroids are Schedule III controlled substances under the Controlled Substances Act, via the Anabolic Steroid Control Act (1990; expanded by the Anabolic Steroid Control Act of 2004, Pub. L. 108-358, signed October 22, 2004, with the steroid-definition amendments effective in January 2005). Boldenone is specifically named in the federal definition of “anabolic steroid” at 21 U.S.C. § 802(41), listed as “boldenone (17β-hydroxyandrost-1,4-diene-3-one).” Boldenone for human use is therefore a Schedule III controlled substance, and non-prescribed human possession or distribution is illegal; its only lawful channel is the FDA-approved veterinary product, handled appropriately. (A 2009 DEA final rule classifying steroids as Schedule III is useful scheduling background but adds boldione and two other steroids — not boldenone itself, which is scheduled directly by statute.) For class context: clenbuterol is not FDA-approved for humans and is not a scheduled controlled substance, and human growth hormone is governed by its own statute (21 U.S.C. § 333(e)) rather than CSA scheduling — neither changes boldenone’s Schedule III status.

In sport, boldenone is a prohibited anabolic agent under Category S1 (S1.1, Anabolic Androgenic Steroids) of the WADA Prohibited List, prohibited at all times (in- and out-of-competition). The 2026 List explicitly covers listed AAS “and other substances with a similar chemical structure or similar biological effect(s), including their esters,” which captures boldenone undecylenate. Misuse is identified by detecting boldenone and its principal metabolite 5β-androst-1-en-17β-ol-3-one; because trace boldenone can arise from non-doping sources in some samples, IRMS (¹³C/¹²C) confirmation is used to establish exogenous origin.

Safety

Boldenone is a foreign androgen with systemic effects and carries the cardiovascular, hormonal, and class-level risks of AAS.

Cardiovascular and lipids: AAS, including non-17-alkylated injectables, strongly suppress HDL cholesterol and raise LDL. Chronic supraphysiologic AAS exposure is associated with hypertension, dyslipidemia, atherosclerosis and early coronary disease, left-ventricular changes and cardiomyopathy, arrhythmia, and sudden cardiac death.
Hepatotoxicity (an important compound-specific distinction): the classic cholestatic, peliosis, and tumor hepatotoxicity is tied to 17α-alkylated oral steroids. Boldenone is not 17α-alkylated and is injectable, so it is not considered a primary hepatotoxin in the way oral 17-alkylated agents are. It remains a foreign androgen with systemic effects.
HPTA suppression and infertility: exogenous androgens suppress the hypothalamic-pituitary-gonadal axis (lower LH/FSH), causing testicular atrophy, impaired spermatogenesis and infertility, reduced endogenous testosterone, and potential post-use secondary hypogonadism with low libido, erectile dysfunction, and mood disturbance.
Estrogenic effects: boldenone aromatizes, so gynecomastia and fluid retention are possible, especially at higher exposures, though typically reported as less than with testosterone.
Virilization (in females): androgenic effects such as deepened voice, hirsutism, menstrual disruption, and clitoral enlargement, some of which can be irreversible.
Hematologic: androgens stimulate erythropoiesis; boldenone can raise red-cell mass and hematocrit (the same effect prized in debilitated horses), which in humans raises blood-viscosity and thrombotic concerns at high hematocrit.
Other class effects: acne, androgenic alopecia, and mood/aggression changes. With illicit injectable use there are added injection-site and sterility/contamination risks: veterinary-grade product is not formulated, labeled, or quality-controlled for human use.

Bottom line

Boldenone is an injectable anabolic-androgenic steroid, not a peptide. Its only sanctioned use today is veterinary (debilitated horses), and there are no modern human clinical trials supporting its lean-mass, strength, or performance claims — those rest on general androgen pharmacology and anecdote. In the US it is a Schedule III controlled substance, specifically named in federal statute, and it is banned at all times in sport. It avoids the oral 17α-alkylated liver-toxicity profile, but it still carries the cardiovascular, lipid, HPTA-suppression, estrogenic, virilizing, and hematologic risks of the AAS class.

Evidence grade: Animal only.

Boldenone (Equipoise)